The global pet cancer therapeutics market, by therapy (Chemotherapy, Targeted Therapy, Combination Therapy, and Immunotherapy), by pet type (Cat, Dog, and Horse), by mode of administration (Oral, Intravenous, and Topical), by application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer, and Others) and by region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa), was evaluated at US$ 183.3 million in 2017 and now expected to exhibit a CAGR of 7.7% over the forecast period (2017-2025).

Rising global awareness about the importance of early diagnosis of pet cancers, adoption of novel therapies with acclaimed safety profiles, growing veterinary healthcare expenditure, multiple drugs currently in the pipeline, and increasing R&D initiatives are significant aspects that offer a major impetus to the global pet cancer therapeutics market growth.

Several globally recognized veterinary pharmaceutical companies have been focusing on strategic collaborations to develop and commercialize certain cancer treatments for companion animals. For instance, Karyopharm and Anivive Lifesciences entered into an exclusive license agreement in 2017, for the research, development, and commercialization of Verdinexor (KPT-335) – a drug intended for the treatment of lymphoma.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/pet-cancer-therapeutics-market-1284

The U.S. FDA Center for Veterinary Medicine (CVM) has found effectiveness and safety technical sections for Verdinexor to support the conditional approval under a New Animal Drug Application (NADA) for the treatment of canine lymphoma. The drug candidate was further granted the Minor Use & Minor Species (MUMS) designation.

The key companies operating in the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zoetis, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, and Oasmia Pharmaceuticals AB.

These market contenders are actively engaged in the development, licensing, and commercialization of effective pet therapeutics. For instance, in 2017, Doxosphos Vet, a patented formulation of doxorubicin and the XR17 technology by Oasmia Pharmaceuticals AB, was developed for the treatment of lymphoma in dogs. The drug candidate was subsequently granted the MUMS designation by the U.S. FDA. Furthermore, in 2015, Rhizen Pharmaceuticals S.A. initiated the Phase 2 study of RV1001, a novel oral selective inhibitor of PI3K delta, which is indicated for the treatment of lymphoma in dogs. Moreover, increasing investments by pet owners in disease treatments propel the growth of the global market. As per an annual survey carried out by the American Pet Products Association in 2015, most people in the U.S. spend an estimated US $15.4 billion on veterinary care each year.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1284
Key Market Takeaways:

• Among therapy types, the chemotherapy segment holds the foremost position in the global pet cancer therapeutics market, primarily owing to the easy availability of chemotherapy drugs.

• Among pet types, the dogs segment dominates the global market, owing to the higher prevalence of cancer among dogs, as compared to the other pets.

• In terms of application, the lymphoma segment leads the global pet cancer therapeutics market, with the largest number of lymphoma cases among pet animals and a huge number of therapeutics approved for this treatment.

• Increasing incidence of pet cancers, and high pet adoption rates in Europe, Asia Pacific, and Latin America act as pivotal market growth boosters.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1284
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737